Anti-BCMA CAR-NK

Phase 2Cell therapy

SShahid Beheshti University of Medical Sciences

Anti-BCMA CAR-NK is one of 39 biologic programs targeting Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaNot yet recruiting

Multiple MyelomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Phase 3

45 2

Belamaf

GSK

Phase 3

39 3

Fludara

Sanofi

Phase 3

47 4

TALVEY

Johnson & Johnson

Phase 3

24 5

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 6

Biaxin

AbbVie

Phase 3

15 7

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 8

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 9

Elranatamab

Vepesid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma

Not yet recruiting·SShahid Beheshti University of Medical Sciences·Phase 1/2·NCT06242249·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-BCMA CAR-NK. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-BCMA CAR-NK compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-BCMA CAR-NK. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shahid Beheshti University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: SShahid Beheshti University of Medical Sciences

Anti-BCMA CAR-NK

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News